Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.

Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.